drugset
drugset / Trial / NCT02068898

Pharmacokinetic Comparison of XS003 and Tasigna

NCT02068898 ↗

Phase 1 Completed 27 enrolled XSpray Microparticles
RandomizedCrossoverOpen-labelTreatment

Summary

The study will assess bioavailability of XS003 given as a single oral dose compared to Tasigna® given as a single oral dose in healthy male subjects.

Timeline

Start
2013-12
Primary completion
2014-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule — Oral
Subject XS003 Unknown — Oral

Indications

No indication recorded.